Abstract
The introduction of the MOPP (mustine, oncovin, procarbazine, and prednisone) combination by DeVita and colleagues (Longo et al. 1986) represented a dramatic advance in the treatment of patients with advanced Hodgkin’s disease. The complete remission (CR) rate at Memorial Hospital was at the lower end of those reported in the literature, perhaps reflecting the inclusion of advanced Hodgkin’s disease patients with a worse prognosis than those seen in other centers.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bonadonna G, Valagussa P, Santoro A (1986) Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin’s disease. Ann Intern Med 104: 739–746
Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971) Report of the committee on Hodgkin’s disease staging. Cancer Res 31: 1860–1861
Cox DR (1972) Regression models and life tables (with discussion). J R Stat Soc Br 24: 187–200
Dinsmore RE, Straus DJ, Pollack MS, Woodruff JM, Garrett TJ, Young CW, Clarkson BD, Dupont B (1980) Fatal graft-vs-host disease following blood transfusion in Hodgkin’s disease documented by HLA typing. Blood 55: 831–834
Jagannath S, Dicke K, Armitage J, Cabanillas FF, Horowitz LD, Vellekoop L, Zander A, Spizer G (1986) High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin’s disease. Ann Intern Med 104: 163–168
Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481
Klimo P, Connors J (1985) MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin’s disease. J Clin On-col 3: 1174–1182
Longo DL, Young RC, Wesley M, Hubbard SM, Duffey PL, Jaffe ES, DeVita VT (1986) Twenty years of MOPP therapy for Hodgkin’s disease. J Clin Oncol 4: 1295–1306
Lukes RJ, Craver LF, Hall TC, Rappaport H, Rubin P (1966) Report of the nomenclature committee. Cancer Res 26: 1311
Santoro A, Bonadonna G, Valagussa P, Zucali R, Vivani S, Villani F, Pagnoni AM, Bonfante V, Musumeci R, Crippa F, Tess JDT, Banfi A (1987) Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin’s disease. Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 5: 27–37
Straus DJ, Myers J, Passe S, Young CW, Nisce LZ, Lee BJ, Gee T, Clarkson BD (1980) The eight drug/radiation therapy program (MOPP/ABVD/RT) for advanced Hodgkin’s disease. A follow-up report. Cancer 46: 233–240
Straus DJ, Myers J, Lee BJ, Nisce LZ, Koziner B, McCormick B, Kempin S, Mertelsmann R, Arlin Z, Gee T, Poussin-Rosillo H, Hansen H, Clarkson BD (1984) Treatment of advanced Hodgkin’s disease with chemotherapy and irradiation. Controlled trial of two versus three alternating, potentially non-cross-resistant drug combinations. Am J Med 76: 270–278
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Straus, D.J. et al. (1989). Results and Prognostic Factors Following Optimal Treatment of Advanced Hodgkin’s Disease. In: Diehl, V., Pfreundschuh, M., Loeffler, M. (eds) New Aspects in the Diagnosis and Treatment of Hodgkin’s Disease. Recent Results in Cancer Research, vol 117. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-83781-4_20
Download citation
DOI: https://doi.org/10.1007/978-3-642-83781-4_20
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-83783-8
Online ISBN: 978-3-642-83781-4
eBook Packages: Springer Book Archive